{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:43:55Z","timestamp":1694605435870},"reference-count":63,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T00:00:00Z","timestamp":1521849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As Type 2 diabetes progresses, treatment is intensified with additional therapies in an effort to manage hyperglycaemia effectively and therefore avoid complications. When greater efficacy is required, options for injectable treatments include glucagon\u2010like peptide\u20101 receptor agonists and insulin, which may be added on to oral glucose\u2010lowering treatments. Among individuals receiving long\u2010acting basal insulin as their first injectable treatment, ~40\u221260% are unable to achieve or maintain their target HbA<jats:sub>1c<\/jats:sub> goals. For these people, treatment intensification options are relatively limited and include the addition of short\u2010acting prandial insulin or a glucagon\u2010like peptide\u20101 receptor agonist. Glucagon\u2010like peptide\u20101 receptor agonists vary in their effects, with short\u2010 and long\u2010acting agents having a greater impact on postprandial and fasting hyperglycaemia, respectively. Studies comparing treatment intensification options have found both glucagon\u2010like peptide\u20101 receptor agonists and prandial insulin to be effective in reducing HbA<jats:sub>1c<\/jats:sub> concentrations; however, recipients of glucagon\u2010like peptide\u20101 receptor agonists lost weight and had a greater frequency of gastrointestinal adverse events, whereas those receiving prandial insulin gained weight and had a greater incidence of hypoglycaemia. In addition to the separate administration of a glucagon\u2010like peptide\u20101 receptor agonist and basal insulin, fixed\u2010ratio combinations of a glucagon\u2010like peptide\u20101 receptor agonist and basal insulin offer a single administration for both treatments but have less flexibility in dose titration than treatment with their individual components. For individuals who require treatment intensification beyond basal insulin, use of these various options allows physicians to target the individual needs of their patients for the achievement of optimal long\u2010term glycaemic control.<\/jats:p>","DOI":"10.1111\/dme.13610","type":"journal-article","created":{"date-parts":[[2018,2,25]],"date-time":"2018-02-25T11:42:35Z","timestamp":1519558955000},"page":"694-706","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of glucagon\u2010like peptide\u20101 receptor agonists among individuals on basal insulin requiring treatment intensification"],"prefix":"10.1111","volume":"35","author":[{"given":"M. E.","family":"Trautmann","sequence":"first","affiliation":[{"name":"Diabetes Research Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Vora","sequence":"additional","affiliation":[{"name":"Diabetes and Endocrinology Royal Liverpool University Hospital Liverpool UK"},{"name":"AstraZeneca Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,24]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.21.2005"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP15693.CS"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.004"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-S008"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70029-4"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2012.699715"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-12-200306170-00006"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP10323.OR"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2016.08.006"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S301"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-014-0555-4"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00482-9"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1090295"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2243"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021545"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-013-0404-x"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-017-1054-2"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0518"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2012.07.2567"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.03006.x"},{"key":"e_1_2_13_25_1","first-page":"643","article-title":"Effects of glucagon\u2010like peptide\u20101 receptor agonists on b\u2010cell function in patients with type 2 diabetes","volume":"7","author":"Grandy S","year":"2016","journal-title":"J Diabetes Metab"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2003.10.028"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61335-0"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0876"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.15277\/bjdvd.2014.015"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199205143262003"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01557.x"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-015-0219-8"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-2-201101180-00300"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.10.001"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_13_41_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2337\/dc15-1274","article-title":"Effect of the GLP\u20101 receptor agonist lixisenatide on counterregulatory responses to hypoglycemia in subjects with insulin\u2010treated type 2 diabetes","volume":"39","author":"Farngren J","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12262"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12539"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3302-0"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12447"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12457"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-142"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.1540"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0001"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP171769.OR"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP14290.OR"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0046"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12980"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12961"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12498"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"key":"e_1_2_13_61_1","unstructured":"BillingsLK DoshiA GouetD OviedoA RodbardHW TentolourisNet\u00a0al.Efficacy and safety of insulin degludec\/liraglutide (IDegLira) vs. basal\u2010bolus (BB) insulin therapy in patients with type 2 diabetes (T2D): DUAL VII trial (OR\u2010136). Presented at: American Diabetes Association (ADA) 2017 Scientific Sessions; June 9\u201313 2017; San Diego CA."},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0094-1"},{"key":"e_1_2_13_63_1","unstructured":"European Medicines Agency. Xultophy Assessment Report.2015. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002647\/WC500192080.pdf. Last accessed 13 July 2017."},{"key":"e_1_2_13_64_1","unstructured":"European Medicines Agency. Xultophy Assessment Report.2014. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002647\/WC500177659.pdf. Last accessed 13 July 2017."}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:56:52Z","timestamp":1694555812000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,24]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/dme.13610"],"URL":"https:\/\/doi.org\/10.1111\/dme.13610","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,24]]},"assertion":[{"value":"2018-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}